• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型 CFHR1-CFHR5 杂合导致家族性显性 C3 肾小球病。

A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.

机构信息

Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche en Santé 1138, Team "Complement and Disease," Cordeliers Research Center, Paris, France; Paris Descartes University, Paris, France.

Kidney and Urology Institute, Medanta, The Medicity Hospital, Gurgaon, Haryana, India.

出版信息

Kidney Int. 2017 Oct;92(4):876-887. doi: 10.1016/j.kint.2017.04.025. Epub 2017 Jul 18.

DOI:10.1016/j.kint.2017.04.025
PMID:28729035
Abstract

The intrinsic similarity shared between the members of the complement factor H family, which comprises complement factor H and five complement factor H-related (CFHR) genes, leads to various recombination events. In turn these events lead to deletions of some genes or abnormal proteins, which are found in patients with atypical hemolytic uremic syndrome or C3 glomerulopathies. Here we describe a novel genetic rearrangement generated from a heterozygous deletion spanning 146 Kbp involving multiple CFHR genes leading to a CFHR1-R5 hybrid protein. This deletion was found in four family members presenting with a familial dominant glomerulopathy histologically classified as an overlap of dense deposit disease and C3 glomerulonephritis. Affected patients exhibited permanently low C3 and factor B levels and high amounts of activation fragments sC5b9 and Bb, indicating a systemic alternative pathway dysregulation. The abnormal protein, characterized by Western blot and immunoprecipitation, was shown to circulate in association with CFHR1 and CFHR2, attributable to its two N-terminal dimerization motifs. The presence of this protein is associated with a perturbation of Factor H activity on the C3 convertase decay. Thus, our study highlights the role of CFHRs in the physiopathology of C3 glomerulopathies and stresses the importance of screening CFHRs in all familial C3 glomerulopathies. Such hybrids described till now were always associated with familial forms.

摘要

补体因子 H 家族成员之间存在内在相似性,该家族由补体因子 H 和五个补体因子 H 相关(CFHR)基因组成,导致了各种重组事件。这些事件反过来导致了一些基因或异常蛋白的缺失,这些异常蛋白在非典型溶血性尿毒症综合征或 C3 肾小球病患者中被发现。在这里,我们描述了一种新型的遗传重排,它是由涉及多个 CFHR 基因的 146 Kbp 杂合缺失产生的,导致 CFHR1-R5 杂合蛋白。该缺失在四个家族成员中发现,这些家族成员表现为家族性显性肾小球病,组织学上分类为密沉积病和 C3 肾小球肾炎的重叠。受影响的患者表现为 C3 和因子 B 水平持续降低,以及大量的激活片段 sC5b9 和 Bb,表明系统性替代途径失调。该异常蛋白通过 Western blot 和免疫沉淀进行了特征描述,它与 CFHR1 和 CFHR2 结合循环,归因于其两个 N 端二聚化基序。该蛋白的存在与 C3 转化酶衰变过程中因子 H 活性的改变有关。因此,我们的研究强调了 CFHRs 在 C3 肾小球病生理病理中的作用,并强调了在所有家族性 C3 肾小球病中筛查 CFHRs 的重要性。到目前为止,描述的这些杂种蛋白总是与家族性形式有关。

相似文献

1
A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.一种新型 CFHR1-CFHR5 杂合导致家族性显性 C3 肾小球病。
Kidney Int. 2017 Oct;92(4):876-887. doi: 10.1016/j.kint.2017.04.025. Epub 2017 Jul 18.
2
Complement factor H-related hybrid protein deregulates complement in dense deposit disease.补体因子 H 相关杂合蛋白在致密物沉积病中调控补体。
J Clin Invest. 2014 Jan;124(1):145-55. doi: 10.1172/JCI71866. Epub 2013 Dec 16.
3
Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.基因变异为肾脏疾病非典型溶血尿毒症综合征和 C3 肾小球病的发病机制提供了新见解。
J Am Soc Nephrol. 2020 Feb;31(2):241-256. doi: 10.1681/ASN.2019050515. Epub 2020 Jan 24.
4
Complement factor H related proteins (CFHRs).补体因子 H 相关蛋白(CFHRs)。
Mol Immunol. 2013 Dec 15;56(3):170-80. doi: 10.1016/j.molimm.2013.06.001. Epub 2013 Jul 3.
5
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.获得性和遗传性补体异常在致密物沉积病和其他 C3 肾小球疾病中起着关键作用。
Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.
6
A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.一种新型非典型溶血尿毒症综合征相关的混合 CFHR1/CFH 基因,编码一种拮抗因子 H 依赖性补体调节的融合蛋白。
J Am Soc Nephrol. 2015 Jan;26(1):209-19. doi: 10.1681/ASN.2013121339. Epub 2014 Jun 5.
7
The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.MFHR1 融合蛋白是一种新型的合成多靶点补体抑制剂,具有治疗潜力。
J Am Soc Nephrol. 2018 Apr;29(4):1141-1153. doi: 10.1681/ASN.2017070738. Epub 2018 Jan 15.
8
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.罕见补体变异的统计学验证为非典型溶血尿毒症综合征和 C3 肾小球病的分子基础提供了新见解。
J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2.
9
Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene.由一种新型CFHR5-CFHR2融合基因引起的家族性C3肾小球肾炎。
Mol Immunol. 2016 Sep;77:89-96. doi: 10.1016/j.molimm.2016.07.007. Epub 2016 Aug 1.
10
Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.C3肾小球病和非典型溶血性尿毒症综合征中补体成分的自身抗体。
Immunol Lett. 2014 Aug;160(2):163-71. doi: 10.1016/j.imlet.2014.01.014. Epub 2014 Feb 1.

引用本文的文献

1
Complement-Mediated Kidney Disease and Living Donor Transplantation: Tailoring Approaches to Improve Outcomes.补体介导的肾脏疾病与活体供肾移植:定制改善预后的方法。
Curr Transplant Rep. 2025;12(1). doi: 10.1007/s40472-025-00466-8. Epub 2025 Apr 16.
2
C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation.C3肾小球病:一种由替代途径失调介导的肾脏疾病。
Front Nephrol. 2024 Oct 29;4:1460146. doi: 10.3389/fneph.2024.1460146. eCollection 2024.
3
Evaluation of the significance of complement-related genes mutations in atypical postinfectious glomerulonephritis: a pilot study.
评价补体相关基因突变在非典型感染后肾小球肾炎中的意义:一项初步研究。
Int Urol Nephrol. 2024 Apr;56(4):1475-1485. doi: 10.1007/s11255-023-03831-7. Epub 2023 Oct 17.
4
The Factor H protein family: The switchers of the complement alternative pathway.补体旁路途径的开关:因子 H 蛋白家族。
Immunol Rev. 2023 Jan;313(1):25-45. doi: 10.1111/imr.13166. Epub 2022 Nov 16.
5
Pitfalls in complement analysis: A systematic literature review of assessing complement activation.补体分析的陷阱:评估补体激活的系统文献回顾。
Front Immunol. 2022 Oct 18;13:1007102. doi: 10.3389/fimmu.2022.1007102. eCollection 2022.
6
Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases.遗传变异性塑造了替代途径补体活性和补体相关疾病的易感性。
Immunol Rev. 2023 Jan;313(1):71-90. doi: 10.1111/imr.13131. Epub 2022 Sep 11.
7
and Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.C3肾小球病和免疫复合物介导的膜增生性肾小球肾炎中的拷贝数变异
Front Genet. 2021 Jun 11;12:670727. doi: 10.3389/fgene.2021.670727. eCollection 2021.
8
A Family Affair: Addressing the Challenges of Factor H and the Related Proteins.家族性疾病:因子 H 及其相关蛋白所面临的挑战。
Front Immunol. 2021 Mar 30;12:660194. doi: 10.3389/fimmu.2021.660194. eCollection 2021.
9
Detection of Genetic Rearrangements in the Regulators of Complement Activation RCA Cluster by High-Throughput Sequencing and MLPA.高通量测序和 MLPA 检测补体激活调节剂 RCA 簇中的基因重排。
Methods Mol Biol. 2021;2227:159-178. doi: 10.1007/978-1-0716-1016-9_16.
10
Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.功能获得性因子 H 相关蛋白 5 损害肾小球补体调节导致肾脏损伤。
Proc Natl Acad Sci U S A. 2021 Mar 30;118(13). doi: 10.1073/pnas.2022722118.